News Report · Endocrinology

Biosimilar Insulins 2026: Access and Interchangeability Guidelines for Lantus and Basaglar

June 12, 2026

Clinical Perspective

Healthcare providers managing diabetes should consider the use of biosimilar insulins, such as Basaglar and Semglee, as effective alternatives to Lantus. The updated WHO guidelines support the interchangeability of these products, indicating comparable safety and efficacy profiles. How can clinicians best educate patients about the transition to biosimilar insulins?

Dr. Amit Desai · Endocrinology

The World Health Organization (WHO) has released updated guidelines for the evaluation and interchangeability of biosimilar insulins, including products like Basaglar and Semglee, aimed at enhancing access and affordability for diabetes management in various populations ^[1].

Clinical Context

Diabetes is a chronic condition that affects millions of people worldwide, leading to significant morbidity and mortality if not managed effectively. Insulin therapy remains a cornerstone of diabetes management, particularly for individuals with type 1 diabetes and advanced type 2 diabetes. However, the high cost of insulin products has created barriers to access, especially in low- and middle-income countries. The introduction of biosimilar insulins presents an opportunity to improve access and reduce costs, making insulin therapy more affordable for patients. The WHO's efforts to standardize and promote the use of biosimilars are crucial in addressing these access challenges and ensuring that patients receive effective diabetes care.

Key Findings

The WHO's updated guidelines on biosimilars emphasize the importance of demonstrating similarity between biosimilar products and their reference biologics, such as Lantus ^[1].
The guidelines aim to facilitate the regulatory approval process for biosimilars, potentially increasing their availability and affordability in various markets ^[2].
Interchangeability of biosimilar insulins, such as Basaglar and Semglee, with their reference products is supported by evidence of comparable efficacy and safety profiles ^[4].
The WHO has noted that while biosimilars can improve access to insulin, their uptake remains low in many regions, necessitating further efforts to educate healthcare providers and patients ^[2].
Cost-effectiveness studies indicate that biosimilar insulins can significantly reduce healthcare costs associated with diabetes management, thereby improving patient adherence to therapy ^[3].
The WHO's biosimilars access toolkit provides resources for manufacturers and policymakers to enhance the availability of these products ^[2].

Safety & Tolerability

Hyperglycemia reported with biosimilar insulins — monitor blood glucose levels during treatment ^[1].
Injection site reactions reported — exact frequency not available in public source summary ^[1].
Allergic reactions reported ^[1].
Weight gain associated with insulin therapy — advise patients on lifestyle modifications ^[1].
Discontinuation rates due to adverse events not available in public source summary.
Complete adverse event profile available in the full prescribing information for biosimilar insulins.

Study Design

The WHO guidelines on biosimilars were developed through a comprehensive review of existing data and expert consultations. The guidelines emphasize the need for rigorous evaluation of biosimilars to ensure they meet the same quality, safety, and efficacy standards as their reference products. Key limitations include the variability in regulatory frameworks across different countries, which may affect the implementation of these guidelines. Ongoing studies are needed to assess long-term outcomes and patient experiences with biosimilar insulins.

FAQ

What are biosimilar insulins approved for?

Biosimilar insulins, such as Basaglar and Semglee, are approved for the treatment of diabetes, providing alternatives to reference products like Lantus. These products aim to improve access and affordability for patients requiring insulin therapy.

How do biosimilar insulins work?

Biosimilar insulins work by mimicking the action of their reference biologics, providing similar pharmacokinetic and pharmacodynamic profiles to manage blood glucose levels in patients with diabetes.

What is the recommended dose of biosimilar insulins?

Full dosing guidance is available in the prescribing information for biosimilar insulins, including Basaglar and Semglee, which may vary based on individual patient needs and clinical circumstances.

What are the most common side effects of biosimilar insulins?

Common side effects include hyperglycemia, injection site reactions, and potential allergic reactions. Monitoring and patient education are essential to manage these effects effectively.

How do biosimilar insulins compare to Lantus?

Biosimilar insulins like Basaglar and Semglee are designed to be interchangeable with Lantus, offering comparable efficacy and safety profiles based on regulatory evaluations and clinical studies.

Biosimilar Insulins 2026: Access and Interchangeability Guidelines for Lantus and Basaglar

Biosimilar Insulins 2026: Access and Interchangeability Guidelines for Lantus and Basaglar

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly drug updates for Endocrinology in your inbox.

Related Drug Updates

FDA Approves Semaglutide for Cardiovascular Risk: 20% MACE Reduction in SELECT Trial

FDA Approves Tirzepatide for Chronic Weight Management: 18% Weight Reduction in SURMOUNT-1 Trial

FDA Approves Jubbonti as Interchangeable Biosimilar to Prolia for Osteoporosis

Verified HCP Portal